Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

<< Previous

Bullboard Posts

Next >>

Post by Polaris570on Jan 15, 2021 10:24pm

311 Views

Post# 32312362

Something interesting I found (Departures Capital)

Departures Capital doesn't talk about Mydecine anymore! Watch the video at the 3:02 and 10:30 minute marks. Aaron from departures capital was asked why he doesn't talk about Mydecine Innovations anymore compared to Mind Med and Luminas. He admits selling his holdings from Mydecine to transfer into MMED and NUMI.

https://www.youtube.com/watch?v=50Mf7csZ4Jc&t=662s

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market